---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290464015.md"
description: "Entera Bio shares are trading higher after the company announced the FDA accepted its plan to conduct a single, randomized, double-blind, placebo-controlled, Phase 3 trial to support a potential New Drug Application submission for EB613."
datetime: "2026-06-22T16:34:51.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290464015.md)
  - [en](https://longbridge.com/en/news/290464015.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290464015.md)
---

# 

Entera Bio shares are trading higher after the company announced the FDA accepted its plan to conduct a single, randomized, double-blind, placebo-controlled, Phase 3 trial to support a potential New Drug Application submission for EB613.

### Related Stocks

- [ENTX.US](https://longbridge.com/en/quote/ENTX.US.md)

## Related News & Research

- [Entera Bio (NASDAQ:ENTX) Announces Earnings Results](https://longbridge.com/en/news/295289580.md)
- [Entera Bio Q2 FY26 net loss widens to $7.3 million; R&D expenses more than double to $3.2 million](https://longbridge.com/en/news/295272747.md)
- [Entera Bio says Phase 2 post-hoc analysis supports anabolic effect of oral EB613 in high-risk postmenopausal osteoporosis patients](https://longbridge.com/en/news/294825410.md)
- [AbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial](https://longbridge.com/en/news/295411236.md)
- [Abcellera posts ABCL635 Phase 2 clinical update presentation on menopause hot flashes](https://longbridge.com/en/news/295400253.md)